Drugs / ManNAc
ManNAc
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01634750 | Sep 2012 → May 2013 | hereditary inclusion-body myopathy | National Human Genome Research Institute (NHGRI) | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06664814 | Jul 2026 → Nov 2027 expected | primary focal segmental glomerulosclerosis | National Human Genome Research Institute (NHGRI) | Recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT04231266 Comparator | Apr 2022 → Jun 2025 overdue | myopathy | Leadiant Biosciences, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02346461 Comparator | Feb 2015 → Dec 2017 | myopathy | National Human Genome Research Institute (NHGRI) | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ManNAc | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06664814 ↗ |
| Known as | N-Acetyl-D-Mannosamine | “This hypothesis is supported by prevention of disease after administration of oral N-acetyl-D-mannosamine (ManNAc) in mouse models of GNE myopathy.” NCT02346461 ↗2“An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis” NCT06664814 ↗ “we propose to provide ManNAc (N-acetyl-D-mannosamine monohydrate) orally as a liquid solution” NCT01634750 ↗ |
| Known as | N-acetyl-D-mannosamine monohydrate | “we propose to provide ManNAc (N-acetyl-D-mannosamine monohydrate) orally as a liquid solution” NCT01634750 ↗ |
| Known as | N-acetylmannosamine | “oral administration of the metabolic SA precursor, N-acetylmannosamine (ManNAc) restored sialylation and reduced proteinuria, suggesting therapeutic potential.” PMID 41630898 ↗ Dec 20251“The uncharged Neu5Ac precursor, N-acetylmannosamine (ManNAc), is under development as an orphan drug for treating GNE myopathy.” PMID 33893973 ↗ Apr 2021 |
| Modality | Small molecule | “is an uncharged monosaccharide” NCT04231266 ↗ |
| Route | Oral | “ManNAc (N-acetyl-D-mannosamine monohydrate) orally as a liquid solution” NCT01634750 ↗ |